RGC
UTHR icon

Roberts, Glore & Co’s United Therapeutics UTHR Stock Holding History

Roberts, Glore & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
+451
New +$254K 0.06% 215

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Roberts, Glore & Co's UTHR Position: Q2 2026 in Review

Roberts, Glore & Co opened a new position in United Therapeutics (UTHR) in Q2 2026: 451 shares worth $244K. The stake represents 0.06% of the portfolio and ranks #215 among its holdings.

875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Roberts, Glore & Co held 451 shares of United Therapeutics worth $244K as of Q2 2026.
  • United Therapeutics was a new Roberts, Glore & Co position in Q2 2026.
  • United Therapeutics made up 0.06% of Roberts, Glore & Co's portfolio in Q2 2026, its #215 holding.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.